Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by Forsbureon May 09, 2016 1:30pm
135 Views
Post# 24854563

Horizon Pharma up today -beat earnings and reaffirms guidanc

Horizon Pharma up today -beat earnings and reaffirms guidanc7:11 am Horizon Pharma beats by $0.03, beats on revs; reaffirms FY16 guidance, announces 5 mln share repurchase (HZNP) :

** HORIZON PHARMA PLC, $15.71, +17.15 pct

The drugmaker reported higher-than-expected Q1 profit and revenue, helped by strong sales of its orphan drugs including Ravicti, Actimmune, Krystexxa and Buphenyl.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities